4.4 Article

In Vitro Characterization of the Metabolic Pathways and Cytochrome P450 Inhibition and Induction Potential of BMS-690514, an ErbB/Vascular Endothelial Growth Factor Receptor Inhibitor

Journal

DRUG METABOLISM AND DISPOSITION
Volume 39, Issue 9, Pages 1658-1667

Publisher

AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS
DOI: 10.1124/dmd.111.039776

Keywords

-

Ask authors/readers for more resources

(3R,4R)-4-Amino-1-((4-((3-methoxyphenyl)amino)pyrrolo[2,1-f] [1,2,4]triazin-5-yl)methyl)-3-piperidinol (BMS-690514) is a potent inhibitor of ErbB human epidermal growth factor receptors (HER1, 2, and 4) and vascular endothelial growth factor receptors 1 to 3 that has been under clinical development for solid tumor malignancies. BMS-690514 is primarily cleared by metabolism with the primary metabolic pathways being direct glucuronidation (M6), hydroxylation (M1, M2, and M37), and O-demethylation (M3). In the current investigation, the metabolic drug-drug interaction potential of BMS-690514 was evaluated in a series of in vitro studies. Reaction phenotyping experiments with cDNA-expressed human cytochrome P450 (P450) and UDP-glucuronosyltransferase (UGT) enzymes and human liver microsomes (HLM) in the presence of P450 or UGT inhibitors suggested that CYP3A4, CYP2D6, and CYP2C9 were the major enzymes responsible for the oxidative metabolism of BMS-690514, whereas both UGT2B4 and UGT2B7 were responsible for the formation of M6. BMS-690514 did not cause direct or time-dependent inhibition of P450 enzymes (IC50 values >= 40 mu M) in incubations with HLM and probe substrates of CYP1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, or 3A4. The compound also did not substantially induce CYP1A1, CYP1A2, CYP2B6, CYP3A4, or UGT1A1 at concentrations up to 10 mu M in cultured human hepatocytes. Considering the submicromolar plasma C-max concentration at the anticipated clinical dose of 200 mg, BMS-690514 is unlikely to cause clinically relevant drug-drug interactions when coadministered with other medications. In addition, because multiple enzymatic clearance pathways are available for the compound, inhibition of an individual metabolic pathway either via coadministered drugs or gene polymorphisms is not expected to cause pronounced (>2-fold) increases in BMS-690514 exposure.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.4
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Biochemical Research Methods

Identification and quantification of signal peptide variants in an IgG1 monoclonal antibody produced in mammalian cell lines

Yunping Huang, Jinmei Fu, Richard Ludwig, Li Tao, Jacob Bongers, Li Ma, Ming Yao, Mingshe Zhu, Tapan Das, Reb Russell

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES (2017)

Article Biochemical Research Methods

Synthesis of unlabelled and stable-isotope-labelled glucuronide metabolites of dapagliflozin and synthesis of stable-isotope-labelled dapagliflozin

Kai Cao, John A. Brailsford, Ming Yao, Janet Caceres-Cortes, Robert Espina, Samuel J. Bonacorsi

JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS (2017)

Article Pharmacology & Pharmacy

LC-MS Differential Analysis for Fast and Sensitive Determination of Biotransformation of Therapeutic Proteins

Ming Yao, Bingming Chen, Weiping Zhao, John T. Mehl, Lingjun Li, Mingshe Zhu

DRUG METABOLISM AND DISPOSITION (2018)

Article Biochemical Research Methods

Quantification of fexofenadine in biological matrices: a review of bioanalytical methods

Ming Yao, Nuggehally R. Srinivas

BIOMEDICAL CHROMATOGRAPHY (2012)

Article Pharmacology & Pharmacy

The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus

Sreeneeranj Kasichayanula, Xiaoni Liu, Melanie Pe Benito, Ming Yao, Marc Pfister, Frank P. LaCreta, William Griffith Humphreys, David W. Boulton

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2013)

Article Pharmacology & Pharmacy

In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans

M. Obermeier, M. Yao, A. Khanna, B. Koplowitz, M. Zhu, W. Li, B. Komoroski, S. Kasichayanula, L. Discenza, W. Washburn, W. Meng, B. A. Ellsworth, J. M. Whaley, W. G. Humphreys

DRUG METABOLISM AND DISPOSITION (2010)

Article Pharmacology & Pharmacy

In Vitro Assessment of Metabolic Drug-Drug Interaction Potential of Apixaban through Cytochrome P450 Phenotyping, Inhibition, and Induction Studies

Lifei Wang, Donglu Zhang, Nirmala Raghavan, Ming Yao, Li Ma, Charles A. Frost, Brad D. Maxwell, Shiang-yuan Chen, Kan He, Theunis C. Goosen, W. Griffith Humphreys, Scott J. Grossman

DRUG METABOLISM AND DISPOSITION (2010)

Article Chemistry, Analytical

Determination of Real Time in Vivo Drug Receptor Occupancy for a Covalent Binding Drug as a Clinical Pharmacodynamic Biomarker by Immunocapture-LC-MS/MS

Naiyu Zheng, Ian M. Catlett, Kristin Taylor, Huidong Gu, Mark A. Pattoli, Robert J. Neely, Wenying Li, Alban Allentoff, Xiling Yuan, Eugene Ciccimaro, Ming Yao, Bethanne M. Warrack, James R. Burke, Yan J. Zhang, Renuka Pillutla, Jianing Zeng

ANALYTICAL CHEMISTRY (2019)

Article Medicine, Research & Experimental

Renal Excretion of Dabigatran: The Potential Role of Multidrug and Toxin Extrusion (MATE) Proteins

Hong Shen, Ming Yao, Michael Sinz, Punit Marathe, A. David Rodrigues, Mingshe Zhu

MOLECULAR PHARMACEUTICS (2019)

Article Pharmacology & Pharmacy

Software-aided detection and structural characterization of cyclic peptide metabolites in biological matrix by high-resolution mass spectrometry

Ming Yao, Tingting Cai, Eva Duchoslav, Li Ma, Xu Guo, Mingshe Zhu

JOURNAL OF PHARMACEUTICAL ANALYSIS (2020)

Article Pharmacology & Pharmacy

Evaluation of Rosuvastatin as an Organic Anion Transporting Polypeptide (OATP) Probe Substrate: In Vitro Transport and In Vivo Disposition in Cynomolgus Monkeys

Hong Shen, Hong Su, Tongtong Liu, Ming Yao, Gabe Mintier, Lun Li, R. Marcus Fancher, Ramaswamy Iyer, Punit Marathe, Yurong Lai, A. David Rodrigues

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)

No Data Available